Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18987568 | SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND | December 2024 | June 2025 | Allow | 6 | 0 | 1 | Yes | No |
| 18968074 | EMULSIFIABLE NEONICOTINOID PESTICIDE CONCENTRATE | December 2024 | February 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 18915221 | AZAINDOLE ROCK INHIBITORS | October 2024 | January 2025 | Allow | 3 | 0 | 0 | No | No |
| 18895223 | METHOD OF TREATING CANCER IN A SUBJECT | September 2024 | March 2025 | Allow | 6 | 0 | 1 | Yes | No |
| 18820199 | NAPHTHALENE ISOXAZOLINE COMPOUND AND APPLICATION THEREOF | August 2024 | December 2024 | Allow | 4 | 0 | 0 | Yes | No |
| 18644728 | NOVEL LIPIDS AND NANOPARTICLE COMPOSITIONS THEREOF | April 2024 | January 2025 | Allow | 9 | 1 | 1 | Yes | No |
| 18629056 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | April 2024 | May 2025 | Allow | 13 | 2 | 0 | Yes | No |
| 18610051 | AZAINDOLE ROCK INHIBITORS | March 2024 | January 2025 | Allow | 10 | 1 | 0 | Yes | No |
| 18590713 | POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | February 2024 | December 2024 | Allow | 10 | 0 | 1 | Yes | No |
| 18436569 | EMULSIFIABLE CONCENTRATE (EC) FORMULATION OF NITENPYRAM | February 2024 | November 2024 | Allow | 9 | 1 | 1 | Yes | No |
| 18547996 | MITOFUSIN ACTIVATORS HAVING AN ENDOCYCLIC-BONDED CARBONYL GROUP AND METHODS FOR USE THEREOF | October 2023 | April 2025 | Allow | 20 | 2 | 1 | No | No |
| 18321266 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | May 2023 | November 2024 | Abandon | 18 | 2 | 1 | No | No |
| 18296752 | Pharmaceutical Composition Of S-Ketamine Hydrochloride | April 2023 | February 2025 | Abandon | 23 | 2 | 0 | No | Yes |
| 17819620 | METHOD TO TREAT MANGANESE TOXICITY AND MANGANESE-INDUCED PARKINSONISM IN HUMANS | August 2022 | June 2025 | Abandon | 34 | 4 | 0 | Yes | No |
| 17865195 | INHIBITORS OF GLUCOSYLCERAMIDE SYNTHASE | July 2022 | June 2025 | Allow | 35 | 0 | 0 | Yes | No |
| 17744502 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SNAKE BITE | May 2022 | December 2024 | Allow | 31 | 3 | 0 | Yes | No |
| 17696267 | ARSINOTHRICIN AND METHODS OF TREATING INFECTIONS USING ARSINOTHRICIN | March 2022 | February 2025 | Allow | 35 | 0 | 1 | Yes | No |
| 17571884 | METHODS OF TREATING MUSCLE CRAMPING AND RELATED COMPOSITIONS | January 2022 | March 2025 | Abandon | 38 | 1 | 0 | Yes | No |
| 17548030 | NON-HORMONAL STEROID MODULATORS OF NF-KAPPA BETA FOR TREATMENT OF DISEASE | December 2021 | April 2025 | Abandon | 40 | 2 | 0 | No | No |
| 17545301 | TREATMENT OF MAJOR DEPRESSIVE DISORDER AND SUICIDAL IDEATIONS THROUGH STIMULATION OF HIPPOCAMPAL NEUROGENESIS UTILIZING PLANT-BASED APPROACHES | December 2021 | January 2025 | Abandon | 37 | 1 | 0 | No | No |
| 17456244 | Antibiotic Compounds | November 2021 | September 2024 | Allow | 34 | 1 | 1 | No | No |
| 17528729 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | November 2021 | January 2025 | Allow | 38 | 1 | 1 | Yes | No |
| 17510326 | THERAPEUTIC METHODS USING DECANOIC ACID AND AMINO ACIDS | October 2021 | August 2024 | Allow | 34 | 2 | 0 | No | No |
| 17605447 | Inhibition of IL-1 Induced Inflammation | October 2021 | February 2025 | Abandon | 40 | 2 | 0 | Yes | No |
| 17493801 | FORMULATIONS FOR EPIDERMAL REPAIR | October 2021 | November 2024 | Allow | 37 | 1 | 1 | Yes | No |
| 17392676 | METHODS OF DELAYING PAIN PROGRESSION AND TREATING PROSTATE CANCER | August 2021 | December 2024 | Allow | 40 | 3 | 0 | Yes | No |
| 17392247 | COMPOSITIONS AND METHODS RELATED TO EXCIPIENTS AND CANNABINOID FORMULATIONS | August 2021 | March 2025 | Allow | 43 | 1 | 1 | No | No |
| 17361754 | METHODS FOR TREATING BENZODIAZEPINE MISUSE/USE DISORDER | June 2021 | October 2024 | Allow | 40 | 4 | 0 | Yes | No |
| 17351880 | COMPANION DIAGNOSTIC TOOL FOR MUTANT P53 REACTIVATING COMPOUNDS | June 2021 | March 2025 | Allow | 45 | 4 | 1 | Yes | No |
| 17299236 | 6-HYDROXY-8-OXATRICYCLO[3.2.1.02,4]OCTANE-2-CARBOXAMIDE DERIVATIVES FOR INDUCING CHONDROGENESIS FOR TREATING JOINT DAMAGE | June 2021 | March 2025 | Allow | 46 | 1 | 1 | No | No |
| 17335597 | OPHTHALMIC COMPOSITION OF BRINZOLAMIDE AND BRIMONIDINE | June 2021 | April 2025 | Abandon | 46 | 3 | 0 | Yes | No |
| 17297752 | IMPROVEMENT IN OR RELATING TO ORGANIC COMPOUNDS | May 2021 | June 2025 | Abandon | 49 | 2 | 0 | No | No |
| 17297038 | EZH2- FGFR INHIBITION IN CANCER | May 2021 | October 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17330131 | MODIFYING THE EXPRESSION LEVEL OF A GENE ENCODING AN CYCLOOXYGENASE ENZYME BY TREATING A HUMAN SUBJECT WITH A NITROXIDE | May 2021 | November 2024 | Abandon | 42 | 5 | 1 | Yes | No |
| 17285916 | PYRIDINYL SULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | April 2021 | July 2024 | Allow | 39 | 2 | 0 | No | No |
| 17231048 | COMPOUNDS FOR PROTECTION OF CELLS | April 2021 | June 2025 | Abandon | 50 | 4 | 1 | No | No |
| 17282344 | Niraparib Salts | April 2021 | May 2024 | Allow | 38 | 2 | 0 | No | No |
| 17277383 | SELECTIVE SALMONELLA OR E. COLI CULTIVATION METHOD, COMPOSITIONS AND USES | March 2021 | April 2025 | Abandon | 49 | 1 | 1 | No | No |
| 17115633 | METHOD OF TREATMENT OF ACTINIC KERATOSES | December 2020 | October 2024 | Abandon | 46 | 4 | 0 | No | No |
| 17071228 | METHODS AND COMPOSITIONS RELATING TO LUNG FUNCTION | October 2020 | March 2025 | Allow | 53 | 8 | 2 | Yes | Yes |
| 16873866 | SMALL MOLECULE DRUGS AND RELATED METHODS FOR TREATMENT OF DISEASES RELATED TO TDP-43, ALPHA-SYNUCLEIN, HUNTINGTIN'S PROTEIN AND TAU PROTEIN OLIGOMER FORMATION | July 2020 | January 2025 | Allow | 54 | 5 | 1 | Yes | No |
| 16684874 | Pharmaceutical Formulations for Subcutaneous Administration | November 2019 | December 2024 | Allow | 60 | 4 | 2 | Yes | No |
| 16614335 | INHIBITORS OF NUCLEOTIDYLTRANSFERASE SUPERFAMILY ENZYMES AS ANTIBIOTICS | November 2019 | June 2025 | Allow | 60 | 7 | 1 | Yes | No |
| 16523230 | COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION | July 2019 | December 2022 | Abandon | 41 | 3 | 1 | No | No |
| 16082090 | PHARMACEUTICAL COMPOSITION FOR TREATING FUNCTIONAL PSYCHIATRIC DISORDERS | September 2018 | April 2025 | Allow | 60 | 3 | 1 | Yes | Yes |
| 15875114 | DELIVERY OF A CHEMOTHERAPY AGENT ACROSS THE BLOOD-BRAIN BARRIER | January 2018 | February 2020 | Allow | 25 | 1 | 1 | No | No |
| 15649585 | COMBINATION PRODUCTS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND METHODS OF PRODUCING OR DOSING OF SAME | July 2017 | November 2019 | Allow | 28 | 3 | 1 | Yes | No |
| 15625151 | USES OF ETHER PHOSPHOLIPIDS IN TREATING DISEASES | June 2017 | January 2020 | Allow | 31 | 4 | 1 | Yes | No |
| 15117340 | Myogenesis Promotor, Muscle Atrophy Inhibitor, Medical Composition and Taz Activator | August 2016 | January 2020 | Allow | 42 | 4 | 1 | Yes | No |
| 14906822 | IMIDAZOLECARBOXAMIDES AND THEIR USE AS FAAH INHIBITORS | January 2016 | June 2019 | Allow | 41 | 3 | 0 | Yes | No |
| 14985474 | GROWTH CONTROL OF ORAL AND SUPERFICIAL ORGANISMS USING GALLIUM COMPOUNDS | December 2015 | December 2019 | Allow | 48 | 3 | 0 | Yes | No |
| 14862072 | COMPOSITIONS AND METHODS FOR TREATING FRIEDREICH'S ATAXIA | September 2015 | April 2019 | Allow | 42 | 2 | 1 | No | No |
| 14563613 | METHODS FOR TREATING NON-HODGKIN'S LYMPHOMA WITH 3-(4-AMINO-1-OXO-1,3-DIHYDRO-ISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE IN COMBINATION WITH A SECOND ACTIVE AGENT | December 2014 | February 2016 | Allow | 14 | 0 | 0 | No | No |
| 14257755 | SYNTHETIC SPILANTHOL AND USE THEREOF | April 2014 | June 2016 | Allow | 26 | 1 | 0 | No | No |
| 14201069 | METHODS FOR TREATING MULTIPLE MYELOMA USING 4-(AMINO)-2-(2,6-DIOXO(3-PIPERIDYL))-ISOINDOLINE-1,3-DIONE IN COMBINATION WITH ANTIBODIES | March 2014 | November 2015 | Allow | 20 | 1 | 1 | No | No |
| 13918692 | COMPOSITIONS AND METHODS FOR TRANSMUCOSAL ABSORPTION | June 2013 | July 2016 | Abandon | 37 | 16 | 1 | Yes | Yes |
| 13886405 | HETEROCYCLIC SUBSTITUTED HEXAHYDROPYRANO[3,4-D][1,3]THIAZIN-2-AMINE COMPOUNDS | May 2013 | February 2014 | Allow | 9 | 0 | 0 | No | No |
| 13818337 | SUBSTITUTED N-PHENETHYLTRIAZOLONEACETAMIDES AND USE THEREOF | April 2013 | July 2015 | Allow | 28 | 2 | 1 | No | No |
| 13738649 | CYCLIC AMIDES | January 2013 | November 2015 | Allow | 34 | 2 | 1 | No | No |
| 13222518 | INSECTICIDAL COMPOUND | August 2011 | November 2012 | Allow | 15 | 0 | 0 | No | No |
| 13011233 | CRYSTALS OF LAQUINIMOD SODIUM, AND PROCESS FOR THE MANUFACTURE THEREOF | January 2011 | September 2013 | Allow | 32 | 1 | 2 | No | No |
| 13011187 | CRYSTALS OF LAQUINIMOD SODIUM, AND PROCESS FOR THE MANUFACTURE THEREOF | January 2011 | October 2013 | Allow | 33 | 1 | 0 | No | No |
| 12664062 | HAIR STYLING COMPOSITION | December 2009 | July 2013 | Allow | 43 | 3 | 0 | Yes | Yes |
| 12578932 | REDUCTION OF INFECTION ASSOCIATED WITH MEDICAL DEVICE | October 2009 | December 2012 | Allow | 38 | 1 | 0 | No | No |
| 12574732 | CONTACT LENS SOLUTION WITH A TERTIARY AMINE OXIDE | October 2009 | May 2015 | Allow | 60 | 3 | 1 | No | Yes |
| 11833530 | PHARMACEUTICAL COMPOSITION FOR IMPROVING ORAL HYGIENE AND METHODS THEREOF | August 2007 | May 2014 | Allow | 60 | 2 | 1 | No | No |
| 11795210 | METHODS AND COMPOSITIONS FOR DECREASING SALIVA PRODUCTION | July 2007 | October 2015 | Allow | 60 | 4 | 1 | No | Yes |
| 11633507 | PHARMACEUTICAL FORMULATION CONTAINING PHENYTOIN SODIUM AND MAGNESIUM STEARATE | December 2006 | August 2012 | Allow | 60 | 6 | 1 | Yes | No |
| 11628266 | THERAPY FOR MULTIPLE SCLEROSIS | December 2006 | June 2012 | Allow | 60 | 6 | 0 | Yes | No |
| 11375346 | ANTIPLAQUE ORAL CARE COMPOSITIONS | March 2006 | June 2012 | Allow | 60 | 7 | 0 | No | Yes |
| 11344725 | APIGENIN FOR CHEMOPREVENTION, AND CHEMOTHERAPY COMBINED WITH THERAPEUTIC REAGENTS | January 2006 | April 2008 | Abandon | 26 | 3 | 1 | Yes | No |
| 10762616 | ASSOCIATION OF FLUCONAZOLE-TINIDAZOLE FOR THE TREATMENT OF VAGINAL INFECTIONS, ITS COMPOSITION, PREPARATION PROCESS AND USAGE | January 2004 | August 2012 | Allow | 60 | 9 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SIMMONS, CHRIS E.
With a 100.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 11.1% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner SIMMONS, CHRIS E works in Art Unit 1622 and has examined 62 patent applications in our dataset. With an allowance rate of 72.6%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 40 months.
Examiner SIMMONS, CHRIS E's allowance rate of 72.6% places them in the 28% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by SIMMONS, CHRIS E receive 2.87 office actions before reaching final disposition. This places the examiner in the 93% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by SIMMONS, CHRIS E is 40 months. This places the examiner in the 7% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +6.2% benefit to allowance rate for applications examined by SIMMONS, CHRIS E. This interview benefit is in the 33% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.
When applicants file an RCE with this examiner, 22.4% of applications are subsequently allowed. This success rate is in the 19% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 34.6% of cases where such amendments are filed. This entry rate is in the 44% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 68% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 85.7% of appeals filed. This is in the 76% percentile among all examiners. Of these withdrawals, 66.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 47.1% are granted (fully or in part). This grant rate is in the 54% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 3.2% of allowed cases (in the 84% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 4.4% of allowed cases (in the 77% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.